Biotech giant Amgen Inc. (NASDAQ:AMGN) is becoming a lower-risk stock in 2014, with the current multiple reflecting low expectations for key pipeline programs.
AMGN shares, which trade 14 times its forward earnings, reflects low expectations for the AMG 145 regulatory and commercial aspects and fear over the safety profile for Kyprolis.
AMG 145 is a human monoclonal antibody that inhibits Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), a protein that reduces the liver's ability to remove LDL-C from the blood. AMG 145 is being investigated as a treatment for hyperlipidemia (high cholesterol). The company announced that all of the pivotal lipid lowering studies of evolocumab completed enrollment and the data are expected in the first quarter of 2014.
[Related -Amgen, Inc. (AMGN) Q3 Earnings Preview: Pipeline In Focus]
Best Recreation Companies To Own In Right Now: Texas Rare Earth Resources Corp (TRER.PK)
Texas Rare Earth Resources Corp., formerly Standard Silver Corporation, incorporated on July 29, 1970. a mining company engaged in the business of the acquisition and development of mineral properties. As of August 31, 2012, it held a nineteen year lease to explore and develop a 950 acre rare earth uranium-beryllium prospect located in Hudspeth County, Texas known as Round Top and prospecting permits covering an adjacent 9,345 acres.
The Company�� principal focus will be on developing a metallurgical process to concentrate or otherwise extract the metals from the Round Top rhyolite. In addition to the Round Top Project, the Company also own title to 12 unpatented mining claims, the Macho group, comprising 240 acres covering the Old Dude Mine, located in Sierra County, New Mexico. Another 18 unpatented mining claims and fractional claims, the HA group, consisting 274 acres cover an andesite hosted vein system similar to and some 10 miles to the southwest of the Macho District.
Advisors' Opinion:- [By Jake Mitchell]
As a speculative play on the industry, I came across Texas Rare Earth Resources (TRER.PK), which is principally focused on its 950 acre Round Top project. A Preliminary Economic Assessment by an independent third party found that there are an estimated over 1 billion metric tonnes of resources containing over 1 billion pounds of rare earth elements. A revised PEA, which was originally projected to have a capital cost of $2.1 billion is now estimated to be between $150 million to $350 million. A key concern in the exploration of these mines is how expensive it is to ultimately extract the rare earths from the ground. If Texas Rare Earth is able to show evidence that cost has been significantly reduced it will be the target of interested parties globally.
5 Best Integrated Utility Stocks To Invest In Right Now: ONEOK Partners L.P.(OKS)
ONEOK Partners, L.P. engages in the gathering, processing, storage, and transportation of natural gas in the United States. The company?s Natural Gas Gathering and Processing segment gathers and processes natural gas produced from crude oil and natural gas wells located in the Mid-Continent region; and gathers natural gas in the Williston Basin, which spans portions of Montana and North Dakota, and the Powder River Basin of Wyoming. Its Natural Gas Pipelines segment primarily owns and operates regulated natural gas transmission pipelines, natural gas storage facilities, and natural gas gathering systems for non-processed gas. It also provides interstate natural gas transportation and storage services. This segment?s interstate natural gas pipeline assets transport natural gas through FERC-regulated interstate natural gas pipelines in North Dakota, Minnesota, Wisconsin, Illinois, Indiana, Kentucky, Tennessee, Oklahoma, Texas, and New Mexico. In addition, it transports intra state natural gas through its assets in Oklahoma; and owns underground natural gas storage facilities in Oklahoma, Kansas, and Texas. Its Natural Gas Liquids segment gathers, fractionates, and treats natural gas liquids (NGLs), as well as stores NGL products primarily in Oklahoma, Kansas, and Texas. This segment owns FERC-regulated natural gas liquids gathering and distribution pipelines in Oklahoma, Kansas, Texas, Wyoming, and Colorado; terminal and storage facilities in Missouri, Nebraska, Iowa, and Illinois; and FERC-regulated natural gas liquids distribution and refined petroleum products pipelines in Kansas, Missouri, Nebraska, Iowa, Illinois, and Indiana that connect its Mid-Continent assets with Midwest markets, including Chicago, Illinois. ONEOK Partners GP serves as the general partner of the company. The company was formerly known as Northern Border Partners, L.P. and changed its name to ONEOK Partners, L.P. in May 2006. The company was founded in 1993 and is based in Tulsa, Oklahoma.
Advisors' Opinion:- [By Lauren Pollock]
Oneok Partners L.P(OKS). on Tuesday said it planned to invest $650 million to $780 million on Bakken Shale projects in North Dakota, including a new natural-gas processing plant. The spending plan is set to run through the second quarter of 2016. Oneok has already announced $6 billion to $6.4 billion in total investments through 2016.
- [By Jim Jubak, Senior Markets Editor, MoneyShow.com]
Units of ONEOK Partners (OKS), a member of my Dividend Income portfolio, have dropped 12.2% from March 28 to the close on August 23. That's brought the yield on this MLP (master limited partnership) to 5.69%.
5 Best Integrated Utility Stocks To Invest In Right Now: ChemoCentryx Inc (CCXI)
ChemoCentryx is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. The Company targets the chemokine system, a network of molecules, including chemokine ligands and their associated receptors, as well as related chemo-attractant receptors, all of which are known to drive inflammation. As of December 31, 2011, the Company had four drug candidates in clinical development. Its drug candidates include Traficet-EN (CCX282, GSK'786 or vercirnon), CCX140, CCX354, CCX168, CCX872, CCX507 and CCX662. The Company is also advancing several additional independent drug candidates through preclinical development. The Company�� wholly owned subsidiary is ChemoCentryx Limited.
The Company's drug candidate Traficet-EN (CCX282, GSK'786), is to control the inflammatory response underlying IBD by targeting the chemokine receptor known as CCR9. The Company has completed nine clinical trials with Traficet-EN in a total of 785 subjects, including five Phase I clinical trials (three in the United States and two in the United Kingdom), one thorough QT study in the United States (an assessment of cardiovascular safety which is required for regulatory approval), and three Phase II clinical trials (one in the Netherlands, the United Kingdom, and the United States, one in Finland and one (PROTECT-1) in Australia, Austria, Belgium, Brazil, Bulgaria, Canada, the Czech Republic, Denmark, France, Germany, Hungary, Israel, the Netherlands, Poland, South Africa, Sweden and the United Kingdom). As of December 31, 2011, the Company�� Traficet-EN drug candidate is in four pivotal Phase III clinical trials being conducted by its partner Glaxo Group Limited (GSK).
The Company's independent drug candidate CCX140, targets the chemokine receptor known as CCR2. CCX140 is a potent and selective antagonist of CCR2 that is found on subsets of monocytes and macrophages, which are cells of th! e immune system. In January 2011, the Company completed a 159-patient randomized Phase II clinical trial, conducted in Australia, the Czech Republic, Germany, Hungary and New Zealand, to assess the safety and tolerability of CCX140 in patients with type 2 diabetes. In addition, CCX140 demonstrated biological activity through a dose-dependent decrease in fasting plasma glucose.
CCX354 targets the chemokine receptor known as CCR1. Synovial fluid from the joints of rheumatoid arthritis (RA) patients contains high levels of activated CCR1 chemokine ligands. The Company completed two Phase I clinical trials in a total of 84 healthy subjects, conducted in Switzerland followed by a Phase I/II clinical trial in 24 patients with stable RA, conducted in Belgium and Romania, and a Phase II proof-of-concept clinical trial in 160 patients with moderate-to-severe RA, conducted in Belgium, the Czech Republic, Germany, Hungary, Poland, Romania and the Ukraine. GSK exercised its option to further develop and commercialize CCX354 in November 2011 and had an exclusive right to initiate a Phase II b clinical trial for CCX354 in RA.
CCX168 targets the chemo-attractant C5a receptor (C5aR), which binds to a biologically activated fragment of the complement protein known as C5. As of December 31, the Company completed a Phase I clinical trial for CCX168, conducted in Switzerland. The Company initiated a Phase II proof-of-concept clinical trial in AAV in the fourth quarter of 2011. Its CCX872 is an independent next generation CCR2 drug candidate for the treatment of metabolic diseases, its CCX507 is an independent drug candidate for the treatment of inflammatory bowel disease (IBD) and CCX662 is an independent drug candidate for the treatment of glioblastoma multiforme (GBM).
The Company competes with Abbott Laboratories, Amgen Inc, AstraZeneca plc, Biogen Idec Inc, Bayer AG, Elan Corporation plc, Glaxo Group Limited, Merck & Co Inc, Merck Serono, Takeda Pharmaceutical Co Ltd, Novartis AG! , Pfizer ! Inc, Reata Pharmaceuticals, Inc., Sanofi SA, Teva Pharmaceutical Industries Ltd, Bristol-Myers Squibb, Incyte Corp and UCB Pharma.
Advisors' Opinion:- [By James E. Brumley]
The last few weeks haven't been particularly encouraging for Crohn's disease sufferers. In August, GlaxoSmithKline (NYSE: GSK) and ChemoCentryx (NASDAQ:CCXI) reported that a jointly-developed Crohn's drug, vercirnon, had failed to meet its late-stage trial endpoints. Though the in-development drug isn't dead in the water (GSK and CCXI could rework the drug, the testing regimen, or use it for other indications), it doesn't look good. Then this month - just a few days ago - Coronado Biosciences Inc. (NASDAQ:CNDO) reported that its Phase 3 trials of Crohn's disease drug TSO had also failed to meet its primary endpoints as well. Like vercirnon, CNDO isn't completely out of luck here with the treatment, but forging ahead with further development of the treatment is grasping at straws. Crohn's sufferers don't need to give up home just yet, however - TNI Biotech Inc. (OTCMKTS:TNIB) appears to have a Crohn's treatment that works, and should be able to sidestep the problems that plagued ChemoCentryx, GlaxoSmithKline, and Coronado Biosciences.
- [By CRWE]
ChemoCentryx, Inc. (Nasdaq:CCXI), reported that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the BioCentury NewsMakers in the Biotech Industry Conference on Friday, September 7, 2012, at 9:30 a.m. Eastern Time at the Millennium Broadway Hotel & Conference Center in New York, NY.
5 Best Integrated Utility Stocks To Invest In Right Now: Vale SA (VALE5)
Vale SA (Vale) is a Brazil-based metals and mining company. The Company services are divided into four segments: Bulk Material, including the extraction of iron ore, manganese and ferroalloys, as well as pellet production; Basic metals, comprising the production of non-ferrous minerals, including nickel, copper and aluminum; Fertilizers, including the production of potash, phosphate and nitrogen; and Logistic services, including cargo transportation for third parties divided into rail transport, port and shipping services. Additionally, Vale is active in investments in joint ventures and associate in other businesses. The Company operates through subsidiaries and jointly-controlled entities, incorporated in Brazil, Chile, Australia, Canada, Switzerland, Mozambique, Singapore and the USA, among others. In December, 2013, the Company sold Sociedad Contractual Minera Tres Valles to Inversiones Porto San Giorgio SA. In December 2013, it sold entire stake in Log-in Logistica Intermodal SA. Advisors' Opinion:- [By Ney Hayashi]
Iron-ore producer Vale SA (VALE5) may be active after agreeing to pay 22.3 billion reais ($9.6 billion) to settle a tax dispute with Brazil over profits at its foreign units. Meatpacker Minerva SA may move after Russia lifted a ban on beef exports from one of its plants.
- [By Harry Suhartono]
The Ibovespa dropped 1.8 percent as iron-ore producer Vale SA (VALE5), whose main export market is China, snapped a two-day gain. Pulp producer Fibria Celulose SA (FIBR3) retreated after posting quarterly earnings that trailed analysts��estimates. Brazil plans to sell dollar bonds due in 2025, creating a new benchmark security in international markets, and buy back notes maturing in as little as four years.
- [By Julia Leite]
Fibria Celulose SA (FIBR3), the world�� largest pulp producer, climbed after settling a tax dispute with Brazil over profits at its foreign units. Iron-ore producer Vale SA (VALE5) gained before a report due this weekend forecast to show manufacturing is still expanding in China, the company�� main export market.
No comments:
Post a Comment